基本情報

写真a

平川 晃弘(ヒラカワ アキヒロ)

Akihiro HIRAKAWA


職名

教授

メールアドレス

a-hirakawa.crc@tmd.ac.jp

ホームページ

http://tmdu-biostat-datascience.com/

研究分野・キーワード

生物統計学、データサイエンス、レギュラトリーサイエンス

分野紹介URL

http://tmdu-biostat-datascience.com/

出身大学院 【 表示 / 非表示

  • 東京理科大学  工学研究科  経営工学専攻  博士課程  修了

取得学位 【 表示 / 非表示

  • 博士(工学)  

経歴(学内) 【 表示 / 非表示

  • 2020年04月
    -
    2021年09月
    東京医科歯科大学 医学部附属病院 中央診療施設等 臨床試験管理センター 教授
  • 2020年11月
    -
    現在
    東京医科歯科大学 大学院医歯学総合研究科 医歯学専攻 環境社会医歯学講座 臨床統計学分野 教授
  • 2021年10月
    -
    2022年07月
    東京医科歯科大学 病院 診療管理部門 臨床試験管理センター 教授
  • 2022年08月
    -
    現在
    東京医科歯科大学 病院 診療管理部門 臨床試験管理センター 教授

経歴(学外) 【 表示 / 非表示

  • 2006年04月
    -
    2011年03月
    独立行政法人医薬品医療機器総合機構 新薬審査第一部・第五部 審査専門員(生物統計担当)
  • 2011年04月
    -
    2012年03月
    東京理科大学 工学部経営工学科 助教
  • 2012年04月
    -
    2017年03月
    名古屋大学医学部附属病院 先端医療・臨床研究支援センター 講師(統計解析室 室長)
  • 2017年04月
    -
    2020年03月
    東京大学大学院 医学系研究科 生物統計情報学講座 特任准教授

所属学協会 【 表示 / 非表示

  • 日本薬剤疫学会

  • 日本臨床試験学会

  • 日本計量生物学会

  • International Biometric Society

  • 日本認知症学会

委員歴 【 表示 / 非表示

  • 日本医科大学認定臨床研究審査委員会 技術専門員
  • 2011年
    -
    2013年
    厚生労働省 医薬食品局 審査管理課 データモニタリング委員会に関するガイドライ作成委員会 委員
  • 2011年
    -
    現在
    独立行政法人医薬品医療機器総合機構 専門委員
  • 2012年
    -
    現在
    日本計量生物学会 評議員
  • 2012年
    -
    現在
    日本計量生物学会 日本計量物学会誌 編集委員
  • 2016年
    -
    現在
    日本統計学会 Japanese Journal of Statistics and Data Science, Associate Editor
  • 2018年
    -
    2020年03月
    日本薬剤疫学会 拡充委員会委員
  • 2020年04月
    -
    現在
    経済産業省「認知症共生社会に向けた製品・サービスの効果検証事業」 プログラムオフィサー
  • 2020年04月
    -
    現在
    Japanese Journal of Clinical Oncology Reviewer Board Member
  • 2020年04月
    -
    現在
    日本臨床腫瘍研究グループ プロトコール委員・中間解析委員
  • 2020年04月
    -
    現在
    日本小児癌研究グループ 生物統計委員会委員
  • 2020年04月
    -
    現在
    東京理科大学総合研究院統計科学研究部門アドバイザイリー委員会 学外委員
  • 2022年09月
    -
    2023年03月
    厚生労働省 認定再生医療等委員会の審査の質向上事業 普及啓発班 委員
  • 2022年10月
    -
    現在
    厚生労働省 先進医療技術審査部会 構成員
  • 2022年11月
    -
    現在
    文部科学省 大学設置・学校法人審議会大学設置分科会 専門委員

▼全件表示

研究分野 【 表示 / 非表示

  • 生物統計学、臨床試験方法論、データサイエンス

資格、免許 【 表示 / 非表示

  • 日本計量生物学会 責任試験統計家

 

研究テーマ 【 表示 / 非表示

  • 変形性膝関節症に対する多血小板血漿(PRP)間接内注射の有効性検証医師主導治験:他施設無作為二重盲検比較試験,2022年 - 2026年

  • 球脊髄性筋萎縮症に対する適正治療エビデンス創出のためのリアルワールドデータベース整備,2022年 - 2024年

  • 変形性関節症膝に対する滑膜幹細胞関節注射の二重盲検試験,2022年 - 2024年

  • 造血細胞移植後の治療抵抗性ウイルス感染症に対する第三者由来複数ウイルス特異的T細胞療法の開発と研究/Study and development of third-party derived multi,2022年 - 2024年

  • 小児から成人をシームレスに対象としたB前駆細胞性急性リンパ性白血病に対する前方視的臨床試験による標準治療の開発研究,2022年 - 2024年

  • 移植免疫寛容を誘導する再生医療等製品「誘導型抑制性T細胞」の医師主導治験と承認申請に向けた取り組み,2022年 - 2024年

  • ウィズコロナに対応した健康ビッグデータプラットフォーム基盤強化と利活用の加速,2022年

  • COVID-19 を含む公衆衛生危機管理上、医薬品等の確保が必要な感染症に係る臨床研究を迅速かつ効率的に進めるための研究,2022年

  • 東京大学大学院における生物統計家育成のための卒後教育まで含めた一貫した教育プログラムの研究開発 ,2021年 - 2025年

  • 独自開発・革新性能の増殖制御型アデノウイルスの骨腫瘍(希少・難治性がん)承認への第Ⅱ相医師主導治験,2021年 - 2023年

  • 初発小児フィラデルフィア染色体陽性急性リンパ性白血病(Ph+ALL)に対する化学療法におけるダサチニブの適正使用推進のための研究開発,2021年 - 2023年

  • 「乳児急性リンパ性白血病の新規治療戦略確立をめざす国際共同第Ⅲ相試験に向けた多施設共同第Ⅱ相臨床試験」開発研究,2021年 - 2023年

  • 臨床試験を主導する研究者の育成を含む臨床試験支援体制の構築と運用,2021年

  • COVID-19感染症に伴う血管内皮障害の発生メカニズムの解明とその制御,2020年 - 2023年

  • 卵巣がんゲノム搭載細胞外小胞による新規リキッドバイオプシー戦略,2020年 - 2023年

  • バスケット型臨床試験における治療効果の異質性評価のための統計的方法論の研究開発,2020年 - 2022年

  • Muse細胞を用いた周産期脳障害の新規治療法開発~探索的臨床試験(医師主導治験)~,2020年 - 2021年

  • 希少疾患領域の医薬品開発を効率化するための小規模臨床試験のデザイン・統計解析法の研究開発とその適正利用のための基本的考え方の策定,2019年 - 2021年

  • 認知症に対する非薬物療法のエビデンス創出に資するデータ品質一元管理センターの基盤構築と継続的研究支援のための体制整備,2019年 - 2021年

  • 小児がん、AYA世代のがんに対する、抗悪性腫瘍薬の適正使用推進に資する多施設共同臨床試験,2019年 - 2020年

  • 誘導型抑制性T細胞を用いた臓器移植における免疫寛容誘導を目指した第1/2相多施設共同医師主導治験,2019年 - 2020年

  • 原発性免疫不全症レジストリ(Primary Immunodeficiency Database in Japan)を活用した臨床研究・医師主導治験のコンセプト策定研究,2019年

  • 独自開発の革新的な増殖制御型アデノウイルスの肉腫への承認申請を目指した医師主導治験,2018年 - 2021年

  • HER2増幅固形癌に対するトラスツズマブ・ペルツズマブ併用療法のバスケットトライアル,2018年 - 2020年

  • デュシェンヌ型筋ジストロフィーに対する革新的ペプチド医薬の実用化,2018年 - 2020年

  • タウリンによるA3243Gミトコンドリア糖尿病に対する disease modifying therapy,2018年 - 2020年

  • 慢性活動性EBウイルス感染症を対象としたJAK1/2阻害剤ルキソリチニブの医師主導治験,2018年 - 2020年

  • 乳児急性リンパ性白血病に対する国際共同第III相試験に向けた多施設共同臨床試験による新規治療戦略の確立研究,2018年 - 2020年

  • 小児Ph染色体陽性白血病に対するチロシンキナーゼ阻害薬の適正使用に関する研究開発,2018年 - 2020年

  • 小児急性リンパ性白血病に対する標準的治療法の確立,2017年 - 2019年

  • がん分子標的薬の長期毒性データに基づく新規ベイズ流用量探索デザインの研究開発,2017年 - 2019年

  • 大規模臨床、ゲノム、不死化細胞リソースを基盤としたオミックス解析による孤発性ALS治療法開発研究,2017年 - 2019年

  • 東京大学大学院における生物統計家育成のための教育カリキュラムの標準化のための研究開発,2016年 - 2020年

  • 筋萎縮性側索硬化症患者の疾患登録システムの研究開発,2016年 - 2018年

  • 男性腹圧性尿失禁に対する低侵襲再生治療のための、自己ヒト皮下脂肪組織由来再生(幹)細胞分離用医療機器の開発研究,2016年 - 2018年

  • 骨髄由来間葉系細胞による顎骨再生療法の評価と臨床展開,2016年 - 2018年

  • がん領域Clinical Innovation Network事業による超希少がんの臨床開発と基盤整備を行う総合研究,2015年 - 2019年

  • 適時適切な医療・ケアを目指した、認知症の人等の全国的な情報登録・追跡を行う研究,2015年 - 2019年

  • 希少疾患における疾患登録展開型デザインの開発,2015年 - 2017年

  • 分子標的薬の特性を考慮したベイズ流用量探索法の研究開発,2015年 - 2016年

  • 癌患者ビッグデータに基づく癌分子標的薬の新たな効果の探索と同定,2015年

  • タウリンによるMELAS脳卒中様発作再発抑制療法の実用化,2014年 - 2017年

  • がんゲノムデータに基づく疾患予後・治療効果予測法の開発に関する基盤研究,2014年

  • 腹腔外発生デスモイド腫瘍患者の実態把握および診療ガイドライン確立に向けた研究,2014年

  • 臨床疫学・生物統計学・レギュラトリーサイエンスに関するメディカル・スタッフ向け教育プログラムの開発,2014年

  • 認知症・生活習慣病研究とビッグデータ解析の融合による画期的な疾患予兆発見の仕組み構築と予防法の開発,2013年 - 2021年

  • 成人固形がんに対する標準治療確立のための基盤研究,2013年 - 2019年

  • 大規模孤発性ALS患者前向きコホートの遺伝子・不死化細胞リソースを用いた病態解明、治療法開発研究,2013年 - 2017年

  • 孤発性筋萎縮性側索硬化症の進行・病像に関連する遺伝子・分子の探索と同定,2013年 - 2015年

  • 抗がん剤併用療法のための縮小回帰に基づく用量探索法の研究,2013年 - 2014年

  • 若年がん患者を取り巻くがん診療・緩和治療支援の政策提言に資する研究,2012年 - 2013年

▼全件表示

競争的資金等の研究課題 【 表示 / 非表示

  • 生物統計学的な観点からのワクチン開発における治験計画の立案の迅速化のための研究

    厚生労働省 : 2021年08月 - 2022年03月

  • がん分子標的薬の長期毒性データに基づく新規ベイズ流用量探索デザインの研究開発

    文部科学省/日本学術振興会 : 2017年 - 2020年

  • バスケット型臨床試験における治療効果の異質性評価のための統計的方法論の研究開発

    文部科学省/日本学術振興会

論文・総説 【 表示 / 非表示

  1. Oda G, Nakagawa T, Mori H, Onishi I, Fujioka T, Mori M, Kubota K, Hanazawa R, Hirakawa A, Ishikawa T, Okamoto K, Uetake H. Factors predicting upstaging from clinical N0 to pN2a/N3a in breast cancer patients. World Journal of Clinical Oncology. 2022.09; 13 (9): 748-757. ( DOI )

  2. Takahashi Y, Yamamoto T, Oyama J, Sugihara G, Shirai Y, Tao S, Takigawa M, Sato H, Sasaki M, Hirakawa A, Takahashi H, Goya M, Sasano T. Increase in Cerebral Blood Flow after Catheter Ablation of Atrial Fibrillation JACC. 2022.09;

  3. Sakaki K, Yoshii T, Arai Y, Torigoe I, Tomori M, Onuma H, Ogawa T, Hirakawa A, Sakai K, Okawa A. Effectiveness of Lumbosacral Orthosis after Discectomy for Lumbar Disc Herniation: A Prospective Comparative Study. Spine. 2022.09; ( PubMed, DOI )

  4. Murata K, Takahashi Y, Inaba O, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Sato H, Hanazawa R, Hirakawa A, Goya M, Sasano T. Efficacy of Left Atrial Posterior Wall Isolation Guided by Lesion Size Prediction Module for Non-paroxysmal Atrial Fibrillation. EP Europace, euac079. 2022.07; ( DOI )

  5. Nakayama K, Shachar S, Finn EH, Sato H, Hirakawa A, Misteli T. Large-scale mapping of positional changes of hypoxia-responsive genes upon activation. Molecular biology of the cell. 2022.07; 33 (8): ar72. ( PubMed, DOI )

  6. Hirakawa A, Sato H, Hanazawa R, Suzuki K, Japanese Alzheimer's Disease Neuroimaging Initiative.. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. Statistics in medicine. 2022.06; 41 (21): 4200-4214. ( PubMed, DOI )

  7. Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial. BMJ OPEN. 2022.04; 12 (4): ( DOI )

  8. Kotani T, Imai K, Ushida T, Moriyama Y, Nakano-Kobayashi T, Osuka S, Tsuda H, Sumigama S, Yamamoto E, Kinoshita F, Hirakawa A, Iwase A, Kikkawa F, Kajiyama H. Pregnancy Outcomes in Women with Thyroid Diseases. JMA journal. 2022.04; 5 (2): 216-223. ( PubMed, DOI )

  9. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, Hirakawa A, Yamada S. Neuromuscular electrical stimulation mitigates muscle weakness in elderly diabetic patients after cardiovascular surgery Annals of Physical and Rehabilitation Medicine. 2022.03; ( DOI )

  10. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, Hirakawa A, Yamada S. Neuromuscular electrical stimulation after cardiovascular surgery mitigates muscle weakness in older individuals with diabetes. Annals of physical and rehabilitation medicine. 2022.03; 101659. ( PubMed, DOI )

  11. Hirakawa A, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical statistics. 2022.01; 21 (3): 691-695. ( PubMed, DOI )

  12. Inose H, Kato T, Sasaki M, Matsukura Y, Hirai T, Yoshii T, Kawabata S, Hirakawa A, Okawa A. Comparison of decompression, decompression plus fusion, and decompression plus stabilization: a long-term follow-up of a prospective, randomized study. The spine journal : official journal of the North American Spine Society. 2021.12; 22 (5): 747-755. ( PubMed, DOI )

  13. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Frontiers in Cardiovascular Medicine. 2021.11; ( DOI )

  14. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan Frontiers in Cardiovascular Medicine. 2021.11;

  15. Noda-Narita S, Kawachi A, Okuyama A, Sadachi R, Hirakawa A, Goto Y, Fujiwara Y, Higashi T, Yonemori K. First-line treatment for lung cancer among Japanese older patients: a real-world analysis of hospital-based cancer registry data PLOS ONE. 2021.09; 16 (9): ( DOI )

  16. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, Hirakawa A, Suzuki T, Kondo T, Leipsic J, NØrgaard B L, Matsuo H.. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived From CTA Using Pressure Wire Assessment as Reference American Journal of Roentgenology. 2021.06; 216 (6): 1492-1499.

  17. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Inaba O, Murata K, Sasaki Y, Yoshimoto D, Kaneko M, Tanimoto Y, Isogai R, Yamashita S, Sato H, Hanazawa R, Hirakawa A, Goya M, Sasano T.. Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation Circulation:Arrhythmia and electrophysiology. 2021.06; 14 (6):

  18. Sugimoto T, Sakurai T, Akatsu H, Doi T, Fujiwara Y, Hirakara A, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Arai H, J-MINT investigators. The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial The Journal of Prevention of Alzheimer's Disease. 2021.06;

  19. Ezaki A, Hirakawa A, Hanaoka H, Uyama Y. . Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis Therapeutic innovation & regulatory science. 2021.06;

  20. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, Hirakawa A, Koike R, Kusuda S. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC pediatrics. 2021.03; 21 (1): 106. ( PubMed, DOI )

  21. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, Hirakawa A, Koike R, Kusuda S.. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection BMC Pediatrics. 2021.03; 21 (1):

  22. Yamada S, Hashizume A, Hijikata Y,Ito D, Kishimoto Y, Iida M, Koike H, Hirakawa A, Katsuno M.. Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis Journal of Neurology,Neurosurgery & Psyychiatry. 2021.03;

  23. Ota H, Omori H, Kawasaki M, Hirakawa A, Matsuo H. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. European heart journal cardiovascular Imaging. 2021.02; 23 (2): 217-228. ( PubMed, DOI )

  24. Ikenouchi T, Inaba O, Takamiya T, Inamura Y, Sato A, Matsumura Y, Sato H, Hirakawa A, Takahashi Y, Goya M, Sasano T, Nitta J. The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation. American heart journal. 2021.01; 231 82-92. ( PubMed, DOI )

  25. Sano T, Kato M, Sassa N, Sadachi R, Hirakawa A, Kamihira O, Hirabayashi T, Nishikimi T, Katsuno S, Kimura T, Hattori R, Gotoh M, Tsuzuki T. pT3 subclassification of renal pelvic cancer considering the tumor location improves the patients' prognostic accuracy. Virchows Archiv : an international journal of pathology. 2021.01; 478 (6): 1089-1097. ( PubMed, DOI )

  26. Kato M, Hirakawa A, Sato H, Hanazawa R, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. International journal of clinical oncology. 2021.01; 26 (4): 764-769. ( PubMed, DOI )

  27. Kawase Y, Omori H, Tanigaki T, Hirakawa A, Hirata T, Ota H, Kikuchi J, Sobue Y, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. In vivo validation of resting full-cycle ratio and diastolic pressure ratio: simultaneous measurement with instantaneous wave-free ratio. Cardiovascular intervention and therapeutics. 2021.01; 36 (1): 74-80. ( PubMed, DOI )

  28. Kawatsu Y, Tsuchida J, Ando S, Hirakawa A, Sozu T. Sample size determination in phase I oncology trials based on selection probability of the maximum tolerated dose. Japanese Journal of Biometrics. 2021; 42 (1): 55-64. ( DOI )

  29. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. Frontiers in oncology. 2021; 11 732525. ( PubMed, DOI )

  30. Kuwatsuka Y, Atsuta Y, Hirakawa A, Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. International journal of hematology. 2020.12; 112 (6): 841-850. ( PubMed, DOI )

  31. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, Hirakawa A, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. Stem cells translational medicine. 2020.12; 10 (4): 542-553. ( PubMed, DOI )

  32. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. International journal of clinical oncology. 2020.12; 25 (12): 2130-2137. ( PubMed, DOI )

  33. Kaneko S, Hirakawa A. Assessment of Overall Treatment Effect in the Presence of Inconsistent Regional Effects in Multiregional Clinical Trials Statistics in Biopharmaceutical Research. 2020.12;

  34. Asano J, Hirakawa A. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharmaceutical statistics. 2020.11; 19 (6): 975-1000. ( PubMed, DOI )

  35. Yokoi K, Hattori M, Satake Y, Tanaka Y, Sato M, Hashizume A, Hori A, Kawashima M, Hirakawa A, Watanabe H, Katsuno M. Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. Scientific reports. 2020.11; 10 (1): 20524. ( PubMed, DOI )

  36. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Kawamura I, Okubo M, Kamiya H, Hirakawa A, Kawasaki M, Nakagawa M, Tsuchiya K, Suzuki Y, Ito T, Terashima M, Kondo T, Suzuki T, Escaned J, Matsuo H. Comparisons of Nonhyperemic Pressure Ratios: Predicting Functional Results of Coronary Revascularization Using Longitudinal Vessel Interrogation. JACC. Cardiovascular interventions. 2020.11; 13 (22): 2688-2698. ( PubMed, DOI )

  37. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y, Japan Adult Leukemia Study Group.. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. International journal of hematology. 2020.11; 113 (3): 395-403. ( PubMed, DOI )

  38. Kato T, Motoji Y, Tamaki M, Inagaki M, Tsunekawa T, Hirakawa A, Okawa Y, Tomita S. Clinical benefits of fast-track rehabilitation program for patients with uncomplicated type B acute aortic dissection. General thoracic and cardiovascular surgery. 2020.11; 68 (11): 1234-1239. ( PubMed, DOI )

  39. Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Nakayama S, Kuwatsuka Y, Mizuno M, Hirakawa A. Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived regenerative cells: Outcome of the ADRESU study. International journal of urology : official journal of the Japanese Urological Association. 2020.10; 27 (10): 859-865. ( PubMed, DOI )

  40. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, Hirakawa A, Suzuki T, Kondo T, Leipsic J, Nørgaard BL, Matsuo H. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived from CT Angiography Using Pressure Wire Assessment as Reference. AJR. American journal of roentgenology. 2020.09; 216 (6): 1492-1499. ( PubMed, DOI )

  41. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. Clinical pharmacology and therapeutics. 2020.09; 108 (3): 596-605. ( PubMed, DOI )

  42. Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, Hirakawa A, Tateishi U, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). Medicine. 2020.08; 99 (32): e21457. ( PubMed, DOI )

  43. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, Hirakawa A, Motoi T, Sakai T, Kobayashi E, Gokita T, Okamoto T, Matsunobu T, Shimizu K, Koike H. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan. Cancer science. 2020.08; 111 (8): 2935-2942. ( PubMed, DOI )

  44. Ushida T, Kotani T, Hayakawa M, Hirakawa A, Sadachi R, Nakamura N, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F. Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. Scientific reports. 2020.06; 10 (1): 9312. ( PubMed, DOI )

  45. Majima S, Wakahara K, Nishio T, Nishio N, Teranishi M, Iwano S, Hirakawa A, Hashimoto N, Sone M, Hasegawa Y.. Bronchial wall thickening is associated with severity of chronic rhinosinusitis. Respiratory Medicine.. 2020.05;

  46. Kaneko S, Hirakawa A, Kakurai Y, Hamada C.. A dose-finding approach for genomic patterns in phase I trials. Journal of Biopharmaceutical Statistics. 2020.04;

  47. Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment. 2020.04; 181 (2): 323-329.

  48. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) Journal of Bone and Mineral Metabolism. 2020.03;

  49. Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. Journal of Neurology, Neurosurgery & Psychiatry,. 2020.03; 91 (3): 254-262.

  50. 小山 隆文, 清水 俊雄, 米盛 勧, 小島 勇貴, 松井 直子, 大熊 ひとみ, 野口 瑛美, 須藤 一起, 平川 晃弘, 沖田 南都子, 都祭 紗和子, 鋤柄 多美恵, 中村 健一, 田村 研治, 山本 昇, 藤原 康弘. MDM2阻害剤を用いた内膜肉腫対象医師主導治験 日本心臓血管外科学会学術総会抄録集. 2020.03; 50回 P23-3. ( 医中誌 )

  51. Hattori M, Tsuboi T, Yokoi K, Tanaka Y, Sato M, Suzuki K, Arahata Y, Hori A, Kawashima M, Hirakawa A, Washimi Y, Watanabe H, Katsuno M.. Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. Journal of Neurology. 2020.02; 267 (5): 1516-1526.

  52. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. The Prostate. 2020.02; 80 (3): 284-290.

  53. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. . MASTER KEY Project: Powering Clinical Development for Rare Cancers through a Platform Trial. Clinical Pharmacology & Therapeutics. 2020.02;

  54. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita T, Shibui S, Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer Cancer. 2020.01; 116 (2): 302-308.

  55. Ushida T,Kotani T, Sadachi R, Hirakawa A, Hayakawa M, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F, for the Neonatal Research Network of Japan. Antenatal Corticosteroids and Outcomes in Preterm Twins. Obstetrics and Gynecology. 2020.01; 135 (6): 1387-1397.

  56. Sakakibara S, Hashimoto R, Katayama T, Kenjyo M, Yokokawa Y, Saito Y, Hirakawa A, Ito M, Nakamura T, Hara K, Hashizume A, Aiba I, Inukai A, Katsuno M. Longitudinal change of DAT SPECT in Parkinson’s disease and multiple system atrophy. Journal of Parkinson's Disease . 2020.01; 10 (1): 123-130.

  57. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism. 2020.01;

  58. Kitase Y, Sato Y, Arai S, Onoda A, Ueda K, Go S, Mimatsu H, Jabary M, Suzuki T, Ito M, Saito A, Hirakawa A, Mukai T, Nagamura-Inoue T, Takahashi Y, Tsuji M, Hayakawa M. Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells. Frontiers in cellular neuroscience. 2020; 14 212. ( PubMed, DOI )

  59. Suzuki K, Hirakawa A, Ihara R, Iwata A, Ishii K, Ikeuchi T, Sun CK, Donohue M, Iwatsubo T, Alzheimer's Disease Neuroimaging Initiative, Japanese Alzheimer's Disease Neuroimaging Initiative.. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2020; 6 (1): e12007. ( PubMed, DOI )

  60. Hirakawa A, Tanaka Y, Kaneko S. . Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. Contemporary Clinical Trial Communications . 2019.12; 16 100489.

  61. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. . A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 2019.10; 106 (4): 803-809.

  62. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, Hirakawa A, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Journal of Neurology. 2019.08; 266 (12): 2952-2961.

  63. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T.. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Prostate. 2019.07; 79 (10): 1065-1070.

  64. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, Hirakawa A, Takahashi Y, Sato Y, Natsume J, Nagoya Collaborative Clinical Research Team.. Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children. Japanese journal of infectious diseases. 2019.07; 72 (4): 237-242. ( PubMed, DOI )

  65. Yokoyama T, Miyahara R, Funasaka K, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Hirooka Y, Hirakawa A, Goto H.. The utility of ultrathin endoscopy with flexible spectral imaging color enhancement for early gastric cancer. Nagoya Journal of Medical Science. 2019.05; 81 (2): 241-248.

  66. Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. Nagoya Journal of Medical Science. 2019.05; 81 (2): 227-232.

  67. Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study Nagoya Journal of Medical Science. 2019.05; 81 (2): 233-239.

  68. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Author Correction: Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Translational psychiatry. 2019.05; 9 (1): 146. ( PubMed, DOI )

  69. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, Hirakawa A, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G.. Increase of arginine dimethylation correlates with the progression and prognosis of ALS Neurology. 2019.04; 92 (16): e1868-e1877.

  70. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Translational Psychiatry. 2019.04; 9 126.

  71. Shimizu S, Tsuchiya S, Hirakawa A, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H.. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. BMC Oral Health,. 2019.04; 19 (1): 69.

  72. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer. 2019.03; 109 84-91.

  73. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T, Araki A, Hijikata Y, Hirakawa A, Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. Journal of Neurology. 2019.03; 266 (5): 1211-1221.

  74. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y.. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. The Oncologist. 2019.02; 24 (2): 266-272.

  75. Kakurai Y, Kaneko S, Hamada C, Hirakawa A (corresponding author. Dose individualization and variable selection using Bayesian Lasso in early phase dose-finding trials. Applied Statistics. 2019.02; 68 (2): 445-460.

  76. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. Modern Pathology. 2019.01; 32 (1): 122-127.

  77. Kada A, Hirakawa A (co-first author), Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T.. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. Contemporary Clinical Trials Communications . 2019.01; 14 100316.

  78. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Correction: Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: A non-inferiority randomized control trial. PloS one. 2019; 14 (6): e0218205. ( PubMed, DOI )

  79. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, Hirakawa A, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. Frontiers in Neurology. 2018.11; 9 987.

  80. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, Hirakawa A, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). BMJ Open. 2018.11; 8 (11): e021759.

  81. 川村 一太, 梶浦 涼, 平川 晃弘, 近藤 武, 鈴木 孝彦, 松尾 仁司. D-SPECTによる安静Tc/負荷Tl 2核種同時撮像プロトコールの診断能 核医学. 2018.11; 55 (Suppl.): S175. ( 医中誌 )

  82. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, Hirakawa A, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a Semiconductor Camera: Comparison with the Rest-Stress 99mTc-Tetrofosmin Protocol. Circulation Journal. 2018.10; 82 (11): 2837-2844.

  83. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T.. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. World Neurosurgery. 2018.10; 118 e818-e824.

  84. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, Hirakawa A, Nakamura T, Katsuno M.. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). BMJ Open. 2018.09; 8 (9): e023041.

  85. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. . The rate of neonatal respiratory distress syndrome/transient tachypnea in the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton pregnancies. Clinica Chimica Acta. 2018.09; 484 293-297.

  86. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. Clinica Chimica Acta. 2018.09; 484 192-196.

  87. Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas. 2018.09; 47 (8): 974-979. ( PubMed, DOI )

  88. Hirakawa A, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: a study protocol for a cluster parallel-group randomized controlled trial. Trials. 2018.09; 19 (1): 510. ( PubMed, DOI )

  89. Hirakawa A, Asano J, Sato H, Teramukai S.. Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trial Communication. 2018.08; 12 1-8.

  90. Kawase Y, Tanigaki T, Hirakawa A, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers Cardiovascular Intervention and Therapeutics. 2018.07; 33 (3): 270-276.

  91. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, Hirakawa A, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. Journal of Cardiology. 2018.05; 71 (5): 458-463.

  92. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, Hirakawa A, Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes Archives of Disease in Childhood. 2018.05; 103 (3): f238-f244.

  93. Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y.. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. Therapeutic Innovation & Regulatory Science. 2018.05; 52 (3): 334-338.

  94. Kimura K, Itoh Y, Okada T, Kubota S, Kawamura M, Nakahara R, Oie Y, Kozai Y, Takase Y, Tsuzuki H, Nishio N, Hiramatsu M, Fujimoto Y, Mizutani T, Hirakawa A, Naganawa S. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas Asian Pacific journal of cancer prevention : APJCP. 2018.05; 19 (5): 1195-1199. ( PubMed, DOI )

  95. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, Hirakawa A, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. Medicine. 2018.04; 97 (17): e0449.

  96. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, Hirakawa A, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Hori A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy Neurology. 2018.04; 90 (17): e1501-e1509.

  97. Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery, and Psychiatry. 2018.04; 90 (5): 529-536.

  98. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer International Journal of Clinical Oncology. 2018.04; 23 (2): 266-274.

  99. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, Hirakawa A, Kinoshita F, Gosho M, Sobue G. Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR research protocols. 2018.03; 7 (3): e69. ( PubMed, DOI )

  100. Imai K, Kotani T, Nakano T, Ushida T, Hirakawa A, Kikkawa F.. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. The Journal of Maternal-Fetal & Neonatal Medicine,. 2018.02; 32 (16): 2633-2637.

  101. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial. PLOS ONE. 2018.02; 13 (2): e0192688.

  102. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, Hirakawa A, Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study Epilepsia. 2018.02; 59 (2): 440-448.

  103. Shimamura F, Hamada C, Matsui S, Hirakawa A(corresponding author). Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. Journal of Biopharmaceutical Statistics. 2018.02; 28 (6): 1025-1037.

  104. Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation Prostate. 2018.01; 78 (1): 11-16.

  105. Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer science. 2018.01; 109 (1): 207-214. ( PubMed, DOI )

  106. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Hirakawa A, Suzuki T, Matsuo H. Postocclusional hyperemia for fractional flow reserve after percutaneous coronary intervention JACC-Cardiovascular Interventions. 2017.12; 10 (12): e005674.

  107. Nomura S, Hirakawa A, Hamada C.. Sample size determination for the current strategy in oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. Journal of Biopharmaceutical Statistics. 2017.12; 28 (4): 589-611.

  108. Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, Inagaki T, Banno H, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. Journal of neurology, neurosurgery, and psychiatry. 2017.12; 88 (12): 1026-1032. ( PubMed, DOI )

  109. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, Hirakawa A, Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination Endoscopy International Open. 2017.11; 5 (11): e1136-e1143.

  110. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma European Journal of Cardio-Thoracic Surgery. 2017.11; 52 (5): 969-974.

  111. Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer Oncotarget. 2017.10; 8 (52): 89811-89823.

  112. Miyamoto K, Ohkawara B, Ito M, Masuda A, Hirakawa A, Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling PLoS One. 2017.09; 12 (9): e0184388.

  113. Shimizu S, Yamamoto T, Nakayama S, Hirakawa A, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol BMC Urology. 2017.09; 17 (1): 89.

  114. Kato T, Tamaki M, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms Heart Vessel. 2017.08; 32 (8): 960-968.

  115. Shimura M, Gosho M, Hirakawa A.. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. Statistics in Medicine. 2017.06; 36 (13): 2067-2080.

  116. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique Neurologia Medico-Chirurgica. 2017.05; 57 (5): 238-245.

  117. Kato T, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit Heart and Vessels. 2017.04; 32 (4): 385-389.

  118. Nakanishi K, Sato Y, Mizutani Y, Ito M, Hirakawa A, Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats Scientific Reports. 2017.03;

  119. Imai K, Kotani T, Tsuda H, Nakano T, Hirakawa A, Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound Ultrasound in medicine and biology. 2017.03; 43 (3): 615-620.

  120. Hirakawa A, Kinoshita F. An Analysis of Japanese Patients Enrolled in Multiregional Clinical Trials in Oncology. Therapeutic innovation & regulatory science. 2017.03; 51 (2): 207-211. ( PubMed, DOI )

  121. 谷垣 徹, 川瀬 世史明, 平川 晃弘, 岡本 修一, 大森 寛行, 平田 哲夫, 菊地 淳, 太田 秀彰, 三宅 泰次, 川村 一太, 大久保 宗則, 松尾 仁司. 計算による冠血流予備量比の診断性能の比較 三次元定量的冠動脈造影と冠動脈CT血管造影の比較(Comparison of Diagnostic Performance of Computed Fractional Flow Reserve: 3-Dimentional Quantitative Coronary Angiography versus Coronary Computed Tomography Angiography) 日本循環器学会学術集会抄録集. 2017.03; 81回 OJ-134. ( 医中誌 )

  122. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer Nagoya Journal of Medical Science. 2017.02; 79 (2): 211-220.

  123. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia Annals of Hematology. 2017.02; 96 (2): 289-297.

  124. Asano J, Hirakawa A (co-first author). Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. Journal of Biopharmaceutical Statistics. 2017.02; 27 (6): 918-932.

  125. Gosho M, Maruo K, Tada K, Hirakawa A.. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. European Journal of Clinical Pharmacology. 2017.01; 73 (6): 779-786.

  126. Sawamura A, Okumura T, Hirakawa A, Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study Circulation Journal. 2017; 82 (3): 699-707.

  127. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, Hirakawa A, Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G. Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy PLoS One. 2016.12; 11 (12): e0168846.

  128. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Prognostic impact of tumour size in completely resected thymic epithelial tumours European Journal of Cardio-Thoracic Surgery. 2016.12; 50 (6): 1068-1074.

  129. Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer Langenbeck's Archives of Surgery. 2016.12; 401 (8): 143-1152.

  130. Yonemori K, Hirakawa A (co-first author), Kawachi A, Kinoshita F, Ohkuma H, Nishikawa T, Kenji T, Fujiwara Y, Takebe N. . Drug induced Interstitial Lung Disease in Oncology Phase I Trials. Cancer Science. 2016.12; 107 (12): 1830-1836.

  131. Gosho M, Maruo K, Ishii R, Hirakawa A. Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. Statistical Methods in Medical Research. 2016.11; 27 (7): 2200-2215.

  132. Hirakawa A, Sato H, Gosho M.. Effect of design specifications in dose-finding trials for combination therapies in oncology. Pharmaceutical Statistics. 2016.11; 15 (6): 531-540.

  133. Sato H, Hirakawa A (co-first author), Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. Statistics in Medicine. 2016.10; 35 (23): 4093-4109.

  134. Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation Biology of Blood and Marrow Transplantation. 2016.09; 22 (9): 1702-1709.

  135. Harano K, Yonemori K, Hirakawa A. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study Breast Cancer. 2016.09; 23 (5): 797-806.

  136. Okuma H, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies British Journal of Cancer. 2016.08; 115 (4): 411-419.

  137. Watanabe H, Atsuta N, Hirakawa A (co-first author), Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN Journal of Neurology, Neurosurgery, and Psychiatry. 2016.08; 87 (8): 851-858.

  138. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma Leukemia. 2016.07; 30 (7): 1568-1579.

  139. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, Hirakawa A, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy Annals of Clinical and Translational Neurology. 2016.06; 23 (3): 537-546.

  140. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group Gynecologic Oncology. 2016.06; 141 (3): 447-453.

  141. Yokoi D, Atsuta N, Watanabe H, Nakamura R, Hirakawa A, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis Journal of Neurology. 2016.06; 263 (6): 1129-1136.

  142. Nagata T, Sobajima H, Ohashi N, Hirakawa A, Katsuno T, Yasuda Y, Matsuo S, Tsuboi N, Maruyama S. Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR More than 30 ml/min/1.73m2 PLoS ONE. 2016.05; 11 (5): e0152306.

  143. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents Oncologist. 2016.04; 21 (4): 508-513.

  144. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group European Journal of Cardio-Thoracic Surgery. 2016.02; 49 (2): 575-579.

  145. Kato M, Tsuzuki T, Kimura K, Hirakawa A, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation Modern Pathology. 2016.02; 29 (2): 166-173.

  146. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group International Journal of Clinical Oncology. 2016.02; 21 168-176.

  147. Imai K, Kotani T, Tsuda H, Mano Y, Nakano T, Ushida T, Li H, Miki R, Sumigama S, Iwase A, Hirakawa A, Ohno K, Toyokuni S, Takeuchi H, Mizuno T, Suzumura A, Kikkawa F. Neuroprotective potential of molecular hydrogen against perinatal brain injury via suppression of activated microglia Free Radical Biology & Medicine. 2016.02; 91 154-163.

  148. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Hirakawa A, Gotoh M. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia Urology. 2016.02; 88 149-154.

  149. Hirakawa A, Sato H. . Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. Statistics in Medicine. 2016.02; 35 (3): 479-480.

  150. Tsuda H, Hirakawa A, Kotani T, Sumigama S, Mano Y, Nakano T, Imai K, Kawabata I, Takahashi Y, Iwagaki S, Kikkawa F. Risk assessment for neonatal RDS/TTN using gestational age and the amniotic lamellar body count in twin pregnancies Clinica Chimica Acta. 2015.12; 7 (451): 301-304.

  151. Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y, Iwase A, Hirakawa A, Asai M, Toyokuni S, Kikkawa F. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury Journal of Clinical Biochemistry and Nutrition. 2015.11; 57 (3): 178-182.

  152. Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX®) Haemophilia. 2015.09; 21 (5): 702-707.

  153. Gosho M, Hirakawa A, Maruo K, Noma H, Sato Y.. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts. Statistical Method in Medical Research. 2015.08; 26 (5): 2389-2406.

  154. Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, Hirakawa A, Yokoi K. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma? Lung Cancer. 2015.07; 89 (1): 38-42.

  155. Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, Hirakawa A, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study Neuromuscular Disorders. 2015.07; 25 (7): 554-562.

  156. Kakurai Y, Hirakawa A, Hamada C.. A dose-finding method based on multiple dosing in two-agent combination phase I trials Journal of Biopharmaceutical Statistics. 2015.07; 25 (5): 1065-1076.

  157. Kato T, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, Hirakawa A, Yokoi K. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma General Thoracic and Cardiovascular Surgery. 2015.06; 63 (6): 343-348.

  158. Watanabe H, Atsuta N, Nakamura R, Hirakawa A (co-first author), Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2015.06; 16 (3-4): 230-236.

  159. Kaneko S, Hirakawa A, Hamada C. . Enhancing the Lasso approach for developing a survival prediction model based on gene expression data. Computational and Mathematical Methods in Medicine. 2015.06; 2015 (259474):

  160. Okada N, Tajima K, Takami Y, Kato W, Kei F, Hibino M, Munakata H, Sakai Y, Hirakawa A, Usui A.. Valve selection for the aortic position in dialysis patients. The Annals of Thoracic Surgery. 2015.05; 99 (5): 1524-1531.

  161. Hirakawa A, Wages NA, Sato H, Matsui S.. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. Statistics in Medicine. 2015.05; 34 (24): 3194-3213.

  162. Hirakawa A and Matsui S.. Operating characteristics of restrictions on skipping dose level for adaptive dose-finding method in two-agent phase I trials. Japanese Journal of Biometrics. 2015.04; 36 (1): 1-12.

  163. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T, Hirata H, Hirakawa A, Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats Developmental Neuroscience. 2015.02; 37 (2): 95-104.

  164. Tsuda H, Kotani T, Sumigama S, Mano Y, Kawabata I, Takahashi Y, Iwagaki S, Hirakawa A, Kikkawa F. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies Clinica Chimica Acta. 2015.02; 441 (20): 75-78.

  165. Kataoka Y, Nishida S, Hirakawa A, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus Endocrine Journal. 2015; 62 (2): 195-200.

  166. Ozeki N, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, Hirakawa A, Yokoi K. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer Interactive Cardiovascular and Thoracic Surgery. 2014.11; 19 (5): 830-837.

  167. Asano J, Hirakawa A, Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. Pharmaceutical Statistics. 2014.07; 13 (6): 357-363.

  168. Yamada S, Hirakawa A. Reply to: appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer Surgery. 2014.05; 155 (5): 959-960.

  169. Goto M, Yamamoto T, Kato M, Majima T, Toriyama K, kamei Y, Matsukawa Y, Hirakawa A, Funahashi Y. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients International Journal of Urology. 2014.05; 21 (3): 294-300.

  170. Hirakawa A, Matsui S.. Response to Letter to the Editor by Drs Wages et al. Statistics in Medicine. 2014.05; 33 (12): 2159-2160.

  171. Taniyama TK, Hashimoto K, Katsumata, N, Hirakawa A, Yonemori K, Yunokawa M,S himizu C,Tamura K, Ando M, Fujiwara Y. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? Current Oncology. 2014.04; 21 (2): 84-90.

  172. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, Sakao Y, Mitsudomi T, Hirakawa A, Yokoi K. Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small cell lung cancer European Journal of Cardio-Thoracic Surgery. 2014.04; 45 (4): 687-692.

  173. Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata N. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan Journal Gynecologic Oncology. 2014.04; 25 (2): 124-129.

  174. Asakawa T, Hirakawa A, Hamada C.. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. Journal of Biopharmaceutical Statistics. 2014.03; 24 (2): 310-325.

  175. Arima H, Wakabayashi T, Nagatani T, Fujii M, Hirakawa A, Murase T, Yambe Y, Yamada T, Yamakawa F, Yamamori I, Yamaguchi M, Oiso Y. Adipsia increases risk of death in patients with central diabetes insipidus Endocrine Journal. 2014; 61 (2): 143-148.

  176. Hirakawa A, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. Current Drug Safety. 2014; 9 (3): 220-226.

  177. Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, Hirakawa A, Yokoi K. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the TNM classification of lung cancer Journal of Thoracic Oncology. 2013.12; 8 (12): 1551-1557.

  178. Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Izumi Y, Morita M, Ogaki K, Taniguchi A, Aiba I, Mizoguchi K, Okamoto K, Hasegawa K, Aoki M, Kawata A, Abe K, Oda M, Konagaya M, Imai T, Nakagawa M, Tsuji S, Kaji R, Nakano I, Sobue G. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients Journal of Neurology, Neurosurgery, and Psychiatry. 2013.12; 84 (12): 1365-1371.

  179. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, Hirakawa A, Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS PLoS ONE. 2013.06; 25 (8): e66969.

  180. Sato Y, Kawataki M, Hirakawa A, Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates Acta Paediatrica. 2013.06; 102 (6): e241-e246.

  181. Hirakawa A, Hamada C, Matsui S.. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. Statistics in Medicine. 2013.05; 32 (26): 4515-4525.

  182. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia Cell Death & Disease. 2013.03; 7 (4): e525.

  183. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer International Journal of Clinical Oncology. 2013.02; 18 (1): 132-138.

  184. Asano J, Hirakawa A, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox’s cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy International Journal of Breast Cancer. 2013;

  185. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. Japanese Journal of Biometrics,. 2013; 34 (1): 21-34.

  186. Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy Journal of Cancer Research and Clinical Oncology. 2012.07; 138 (7): 1249-1257.

  187. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. Cancer Informatics. 2012.07; 11 29-39.

  188. Hirakawa A.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. Statistics in Medicine. 2012.03; 31 (6): 516-532.

  189. Hirakawa A, Hamada C, Yoshimura I.. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. Journal of Biopharmaceutical Statistics. 2012.01; 22 (2): 260-275.

  190. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer Biological & Pharmaceutical Bulletin. 2012; 35 (5): 717-724.

  191. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamotoro H, Hirata T, Ando M, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara Y. An analysis of guidance for proper usage documents for oncology drugs in Japan Pharmaceutical Medicine. 2012; 26 165-170.

  192. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal PLoS ONE. 2012; 7 (8): e44393.

  193. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma PLoS ONE. 2012; 7 (1): e31181.

  194. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011.12; 159 (2): 394-398.

  195. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients European Respiratory Journal. 2011.12; 38 (6): 1425-1430.

  196. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma Annals of Surgical Oncology. 2011.10; 18 (10): 2841-2850.

  197. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious “drug lag” for oncology in Japan Investigational New Drugs. 2011.08; 29 (4): 706-712.

  198. Hirakawa A, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. Statistics and Probability Letters. 2011.07; 81 (7): 870-875.

  199. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Compliance with good clinical practice in oncology registration trials in Japan Annals of Oncology. 2011.06; 22 (6): 1451-1456.

  200. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer Medical Oncology. 2011.06; 28 (2): 434-440.

  201. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma European Journal of Dermatology. 2011.06; 21 (4): 539-545.

  202. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? Journal of Geriatric Oncology. 2011.01; 2 (1): 25-30.

  203. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, Hirakawa A, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy Annals of Oncology. 2010.11; 21 (11): 2195-2200.

  204. Ando Y, Hirakawa A. . Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”. Statistics in Biopharmaceutical Research. 2010.11; 2 (4): 462-465.

  205. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registration trials for oncology drug applications in Japan Annals of Oncology. 2010.10; 21 (10): 2112-2118.

  206. Ando Y, Hirakawa A, Uyama Y.. Adaptive clinical trials for new drug applications in Japan. European Neuropsychopharmacology. 2010.10; 21 (2): 175-179.

  207. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy Journal of Surgical Oncology. 2010.05; 101 (3): 222-227.

  208. Yonemori K, Kouno T, Ando M, Hirakawa A, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary non-seminomatous germ cell tumor Oncology. 2010; 78 (1): 34-39.

  209. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer British Journal of Cancer. 2009.11; 101 (9): 1529-1536.

  210. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site British Journal of Cancer. 2009.01; 100 (1): 50-55.

  211. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experiments. Bioinformatics and Biology Insights. 2008.02; 29 (2): 145-156.

  212. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identifying differentially expressed genes in microarray data analysis. Cancer Informatics. 2007.02; 3 (6): 140-148.

  213. 平川 晃弘. 【現代の臨床研究のための統計学2022-洗練された研究デザインと統計解析を理解してみよう】臨床試験の方法 生存時間データの統計解析 医学のあゆみ. 2022.01; 280 (5): 390-395. ( 医中誌 )

  214. 平川 晃弘, 佐藤 宏征, 井桁 正尭, 藤川 桂, 堀口 剛, 大門 貴志, 手良向 聡. 希少疾患領域の治験におけるベイズ流アプローチの利用可能性と留意事項 薬理と治療. 2021.09; 49 (Suppl.1): s72-s79. ( 医中誌 )

  215. 平川 晃弘, 佐藤 宏征. リハビリテーション職種が知っておくべき臨床統計 基礎から最新の話題まで 生存時間解析 Journal of Clinical Rehabilitation. 2021.08; 30 (9): 977-981. ( 医中誌 )

  216. 平川 晃弘. 【臨床研究における生物統計学の新たな貢献】がん臨床試験におけるマスタープロトコル Precision Medicine. 2020.11; 3 (13): 1194-1197. ( 医中誌 )

  217. 横井 克典, 服部 誠, 佐竹 勇紀, 平川 晃弘, 勝野 雅央. 健康診断の結果を用いたParkinson病の発症前バイオマーカーの検索 臨床神経学. 2020.11; 60 (Suppl.): S339. ( 医中誌 )

  218. 松山 奈央, 清水 忍, 片山 朱美, 平川 晃弘, 安藤 昌彦, 上田 一仁, 鈴木 俊彦, 佐藤 義朗. SHIELD試験の立ち上げ 低体温療法を実施した新生児低酸素性虚血性脳症に対するCL2020の安全性及び忍容性を検討する用量漸増臨床試験 臨床薬理. 2020.10; 51 (Suppl.): S340. ( 医中誌 )

  219. 平川 晃弘, 佐立 崚. 小児がん臨床研究の統計的デザイン ランダム化比較試験の統計的要点 日本小児血液・がん学会雑誌. 2020.02; 56 (5): 432-435. ( 医中誌 )

  220. 熱田 直樹, 横井 大知, 平川 晃弘, 林 直毅, 中村 良一, 伊藤 瑞規, 渡辺 宏久, 勝野 雅央, 和泉 唯信, 森田 光哉, 谷口 彰, 狩野 修, 桑原 聡, 青木 正志, 金井 数明, 小野寺 理, 梶 龍兒, 祖父江 元, JaCALS. ALS患者の生存期間に与える非侵襲的換気補助療法の影響 レジストリを用いた解析 臨床神経学. 2019.11; 59 (Suppl.): S358. ( 医中誌 )

  221. 遠藤 明史, 今井 耕輔, 神谷 尚宏, 磯田 健志, 柳町 昌克, 高木 正稔, 金兼 弘和, 森尾 友宏, 平川 晃弘, 小池 竜司. 原発性免疫不全症データベース(PIDJ)を活用した希少疾患の臨床開発プラットフォームの構築 臨床薬理. 2019.11; 50 (Suppl.): S259. ( 医中誌 )

  222. 松本 俊夫, 山本 一彦, 竹内 勤, 田中 良哉, 田中 栄, 伊東 昌子, 中野 哲雄, 平川 晃弘, 宗圓 聰. ステロイド性骨粗鬆症に対するエルデカルシトールの臨床的有用性に関する検討 e-GLORIA試験 日本骨代謝学会学術集会プログラム抄録集. 2019.09; 37回 209. ( 医中誌 )

  223. 宗圓 聰, 山本 一彦, 竹内 勤, 田中 良哉, 田中 栄, 伊東 昌子, 中野 哲雄, 萩野 浩, 平川 晃弘, 松本 俊夫. ステロイド性骨粗鬆症に対するミノドロン酸水和物の臨床的有用性に関する検討 日本骨粗鬆症学会雑誌. 2019.09; 5 (Suppl.1): 294. ( 医中誌 )

  224. 瀧野 皓哉, 山田 純生, 原 康貴, 作井 大介, 久世 洋嗣, 永井 敬志, 加藤 貴吉, 川村 一太, 平川 晃弘, 富田 伸司. 冠動脈バイパス術後患者における術後高血糖は術後筋力低下を引き起こす要因かもしれない 日本循環器学会学術集会抄録集. 2019.03; 83回 CP25-5. ( 医中誌 )

  225. 平川晃弘,浅野淳一,佐藤宏征,橋本大哉,手良向聡. がん臨床試験におけるベイズ流バスケットデザインの理論と実装 計量生物学. 2019; 39 103-122.

  226. 大熊ひとみ,平川晃弘,米盛勧. MASTER KEYプロジェクト-希少がんに対するレジストリ・バスケット臨床研究 腫瘍内科. 2019; 22 435-442.

  227. 平川晃弘,浅野淳一,佐藤宏征,手良向聡. マスタープロトコルに基づくがん臨床試験 計量生物学. 2019; 39 85-101.

  228. 大熊 ひとみ, 平川 晃弘, 米盛 勧. 【頭頸部がん・甲状腺がん・希少がん】希少がん MASTER KEYプロジェクト-希少がんに対するレジストリ・バスケット臨床研究 腫瘍内科. 2018.10; 22 (4): 435-442. ( 医中誌 )

  229. 平川 晃弘. 小児がん臨床研究の統計的デザイン ランダム化対照試験 日本小児血液・がん学会雑誌. 2018.10; 55 (4): 188. ( 医中誌 )

  230. 平川 晃弘. 感染制御のエビデンスを作る 臨床研究における研究計画書作成の統計学的ポイント 日本環境感染学会総会プログラム・抄録集. 2018.02; 33回 25. ( 医中誌 )

  231. 大熊ひとみ,平川晃弘,米盛勧. 希少がんに対する新薬開発の取り組みと課題~MASTER KEYプロジェクト~ 血液内科. 2018; 76 806-812.

  232. 大熊ひとみ,平川晃弘,米盛勧,川井章. MSTER KEYプロジェクト がん分子標的治療. 2018; 16 16-20.

  233. 河知 あすか, 米盛 勧, 西川 忠暁, 川崎 真実子, 柴田 大朗, 安藤 正志, 平川 晃弘, 上田 孝文, 尾崎 敏文, 川井 章. 明細胞肉腫・胞巣状軟部肉腫に対する我が国の試験開発について(OSCAR試験をはじめとして) 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集. 2017.05; 33回 149. ( 医中誌 )

  234. 小川 実加, 鈴木 伸明, 竹下 享典, 内藤 真理子, 平川 晃弘, 笹木 優賢, 兼松 毅, 小嶋 哲人, 若井 建志, 清井 仁, 松下 正. 血友病患者における加齢性変化と動脈硬化関連疾患の検討 日本血栓止血学会誌. 2017.04; 28 (2): 222. ( 医中誌 )

  235. 小川 千香子, 三浦 清邦, 伊藤 祐史, 城所 博之, 平川 晃弘, 根来 民子, 夏目 淳. 重症心身障害児を持つ親の離婚 日本小児科学会雑誌. 2017.03; 121 (3): 563-570. ( 医中誌 )

  236. 伊藤祐史, 三浦清邦, 原紳也, 岸本泰明, 平川晃弘, 小川千香子, 城所博之, 奥村直哉, 梶田光春, 夏目淳. 重度肢体不自由児の救急外来受診と入院医療 日本小児科学会雑誌. 2016; 120 356-366.

  237. 平川晃弘,木下文恵,森由美子,清水忍. 抗悪性腫瘍薬の臨床データパッケージ分析からみる今後の課題 医薬品医療機器レギュラトリーサイエンス. 2015; 46 714-720.

  238. 斉藤真理, 龍島靖明, 米盛勧, 平川晃弘, 文靖子, 西垣玲奈, 牧野好倫, 岩瀬治雄, 安藤正志, 藤原康弘, 林憲一. 製薬企業発行の抗悪性腫瘍薬剤患者説明用パンフレットの現状調査 日本病院薬剤師会雑誌. 2015; 51 877-881.

  239. 平川晃弘,松井茂之. がん第I相試験における2剤併用療法の用量探索法:最近の展開 計量生物学. 2013; 34 81-97.

  240. 安藤友紀,平川晃弘. サロゲートエンドポイントの課題と展望~薬事行政の立場から~ 医薬ジャーナル. 2011; 47 73-75.

▼全件表示

書籍等出版物 【 表示 / 非表示

  1. Daimon T, Hirakawa A, Matsui S. Dose-Finding Designs for Early Phase Cancer Clinical Trials. Springer, 2019

  2. Hirakawa A, Sato H, Daimon T, Matsui S. Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted. Springer, 2018

  3. Hirakawa A, Sato H. Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer, 2017

  4. Hirakawa A, Matsui S. Developments in Statistical Evaluation of Clinical Trials. Springer, 2014

  5. Daimon T, Hirakawa A, Matsui S. Design and Analysis of Clinical Trials for Predictive Medicine. CRC Press, 2014

  6. 内田一郎,芹生卓. 製薬医学入門:くすりの価値最大化をめざして. メディカンル・サイエンス・インターナショナル, 2022 臨床試験のデザインと統計解析

  7. 前田圭介,室谷健太. 生存時間データの分析.臨床研究アウトプット術. 中外医学社, 2020

  8. 平川晃弘,五所正彦. 臨床試験のためのアダプティブデザイン. 朝倉書店, 2018

  9. スーザン・エレンバーグ,トーマス・フレミング,デビット・デメッツ. 臨床試験のためのデータモニタリング委員会:実践ハンドブック. サイエンティスト社, 2017

  10. デビッド・ホスマー,スタンリー・レメショウ,スーザン・メイ. 生存時間解析入門 [原著第2版]. 東京大学出版会, 2014

▼全件表示

講演・口頭発表等 【 表示 / 非表示

  1. Sato H, Sasaki M, Hirakawa A. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

  2. Ikeda S, Kudo R, Yamashita, Y, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Tateishi U, Hirakawa A, Akita H, Matsubara H, Nishihara H, Ishioka C, Sueoka-Aragane N, Muto M, Toyooka S. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. . Annual Meeting, American Society of Clinical Oncology 2022.06.05

  3. Arakawa A, Ozawa H, Hirakawa A, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando R, Terashima K, Nakamura K, Ogawa C. A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.. Annual Meeting, American Society of Clinical Oncology 2022.06.03

  4. Kojima Y, Shimizu T, Yonemori K, Koyama T, Matsui N, Kamikura M, Tomatsuri S, Sumiyoshi Okuma H, Shimoi T, Noguchi E, Sudo K, Hirakawa A, Sadachi S, Okita N, Nakamura K, Yamamoto N, Fujiwara Y.. A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra- rare cancer with a highly life-threatening unmet needs(NCCH1806/MK004). ESMO Congress 2021 2021.09.16

  5. Hasegawa K, Nishikawa T, Hirakawa A, Kawasaki M, Tomatsuri S, Nagasaka Y, Nakamura K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Yoshida H, Yonemori K. . Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL. . ESMO Congress 2021 2021.09.16

  6. Kudo R, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Akita H, Matsubara H, Nishihara H, Ishioka C, Aragane N, Muto M, Toyooka S,1 Tateishi U, Hirakawa A, Miyake S, Ikeda S.. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). ASCO 2021.06.04

  7. Kawai A, Nishikawa T, Kawasaki M, Tomatsuri S, Okamura N, Ogawa G, Hirakawa A, Shibata T, Nakamura K, Kakunaga S, Tamura K, Ando M, Ozaki T, Ueda T, Yonemori K. . Efficacy and Safety of Nivolumab Monotherapy in Patients with Unresectable Clear Cell Sarcoma and Alveolar Soft Part Sarcoma (OSCAR t rial, NCCH1510): A Multicenter, Phase 2 Clinical Trial OSCAR.. CTOS 2020 Annual Meeting 2020.11.18

  8. Asano J, Hirakawa A.. An Empirical Bayesian Basket Trial Design Accounting for Uncertainties of Homogeneity and Heterogeneity of Treatment Effect among Subpopulations. . ENAR 2020 Spring Meeting 2020.03.22

  9. Hirakawa A. An experience of data sharing utilization. 第16回DIA日本年会 2019.11.11

  10. Hirakawa A. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: application to basket trial data. 6th International Society of Biopharmaceutical Statistics 2019.08.26

  11. Hirakawa A. Single-pivotal basket trials for rare cancer development in Japan.. 2019 the Japanese Society of Medical Oncology Annual Meeting, 2019.07.19

  12. Hirakawa A. A clustering-based basket design. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

  13. Hirakawa A. . A clustering-based basket design.. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

  14. Hirakawa A, Sadachi R. A Basket Trial Design using Bayesian Model Averaging. ENAR 2019 Spring Meeting 2019.03.24

  15. Tanaka Y, Sozu T, Hirakawa A.. Dose-Finding Method for Molecularly Targeted Agents Incorporating the Relative Dose Intensity in Phase I Oncology Clinical Trials.. ENAR 2019 Spring Meeting 2019.03.24

  16. Sadachi R, Hirakawa A.. Heterogeneity Assessment of Treatment Effect among Subpopulations in Basket Trials. . ENAR 2019 Spring Meeting 2019.03.24

  17. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, Hirakawa A, Sakai T, Shimizu K, Kobayashi E, Gokita T, Okamoto T, Matsunobu, T. . Significant risk factors of local recurrence after surgery in extra-peritoneal desmoid-type fibromatosis: a multicenter study in Japan.. The CTOS 2018 Annual Meeting 2018.11.14

  18. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. . MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ESMO 2018.10.19

  19. Hirakawa A. Adaptive Designs in Clinical Trials. ICPM 2018: 20th International Conference on Psychosomatic Medicine 2018.09.27

  20. Asano J, Hirakawa A.. An evaluation and modification of Simon's basket design in oncology. . International Society of Clinical Biostatistics 2018.08.26

  21. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y.. MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ASCO 2018.06.01

  22. Hirakawa A. Two-stage dose and zone finding method for two agent combination phase 1/2 trials. 2nd Pacific Rim Cancer Biostatistics Workshop 2017.10.12

  23. Hirakawa A. . Two-stage dose and zone finding method for two agent combination phase 1/2 trials.. Pacific Rim Cancer Biostatistics Workshop 2017.10.12

  24. Hirakawa A. Statistical Consideration for Novel Dose Escalation Methods in Phase 1 Oncology Trials. 2nd NCCH Workshop 2017.07.23

  25. Kakurai Y, Hirakawa A, Hamada C. . Dose individualization based on multiple gene mutations for molecularly targeted agents.. 日本計量生物学会年会 2017.03.16

  26. Hirakawa A, Kakurai Y, Kaneko S, Hamada C. Dose individualization based on multiple gene mutations for molecularly targeted agents. 37th International Society for Clinical Biostatistics 2016.08.21

  27. Hirata T, Kawase Y, Kikuchi J, Hirakawa A, Okamoto S, Omori H, Nakatani Y, Ota H, Saigusa T, Miyake T, Kawamura I, Okubo M, Tsuchiya K, Matsuo H.. The validation of the ischemic cut off of IFR and IFRa (During Hyperemia), to predict the ischemic threshold of FFR.. 第80回日本循環器学会学術集会 2016.03.18

  28. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Arioka Y, Oya-Ito T, Kushima I, Nakamura Y, Shiino T, Mori D, Maeda T, Tanaka S, Hamada S, Noma H, Yoshida M, Noda Y, Nagai T, Yamada K, Ozaki N.. The development of molecular diagnostic tool for schizophrenia using lymphoblastoid cell lines.. US HUPO 2016 Conference 2016.03.13

  29. Hirakawa A. A Data-Driven Clustering Method Using a Mixture Approach of Nonlinear Mixed-Effects Model for Longitudinal Functional Rating Scale in Amyotrophic Lateral Sclerosis Patients. East Asia Regional Biometric Conference 2015 2015.12.20

  30. Shimamura F, Hirakawa A, Hamada C.. Dose Finding Design for Two-Agent Combination Trials. . East Asia Regional Biometric Conference 2015 2015.12.20

  31. Kaneko S, Hirakawa A, Hamada C.. Establishing Individualized Treatment Rules Based on Bayesian Model Averaging Approach.. East Asia Regional Biometric Conference 2015 2015.12.20

  32. Sato H, Hirakawa A, Hamada C.. An Adaptive Dose-Finding Method Using a Change-Point Model for Molecularly Targeted Agents in Phase I Trials.. East Asia Regional Biometric Conference 2015 2015.12.20

  33. Shimoi T, Yonemori K, Hirakawa A, Kinoshita F, Bun S, Shimomura S, Kodaira M, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. . Is there a relationship between oncology drugs’ costs and efficacy? . European Society for Medical Oncology 2015.09.25

  34. Kawachi A, Yonemori K, Hirakawa A, Kinoshita F, Tamura K, Fujiwara Y, Takebe N. . Incidence and risk factors in interstitial lung disease in Cancer Therapy Evaluation Program phase I trials. . European Society for Medical Oncology 2015.09.25

  35. Shimura M, Gosho M, Hirakawa A.. A comparison of conditional bias-adjusted estimators of a treatment difference for continuous data in group sequential designs.. Royal Statistical Society 2015.09.07

  36. Asano J, Hirakawa A.. A novel C-statistic for evaluating prediction accuracy in a cure model for censored survival data with long-term survivors. . 36th Annual Conference of the International for Clinical Biostatistics 2015.08.23

  37. Hirakawa A. Dose-finding designs for combination therapies in oncology. 1st Pacific Rim Cancer Biostatistics Workshop 2015.08.14

  38. Hashimoto J, Koizumi F, Okuma H, Hirakawa A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.. Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis. 第13回日本臨床腫瘍学会学術集会 2015.07.16

  39. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saiot T. . Optimal debulking surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.. 2015 Annual Meeting of the American Society of Clinical Oncology 2015.05.29

  40. Sato H, Hirakawa A, Hamada C.. Dose-finding approach based on efficacy and toxicity outcomes in phase I oncology trials for molecularly targeted agents.. The 2015 ENAR Spring Meet 2015.03.11

  41. Shimada K, Shimada S, Sugimoto K, Hayakawa F, Katayama M, Hirakawa A, Takagi Y, Nakamura S, Seto M, Naoe T, Tomita A, Kiyoi H.. Development and analysis of novel intravascular large B-cell lymphoma NOD/Shi-scid IL2Rγnull mouse xenograft model.. The 56th Annual Meeting of the American Society of Hematology 2014.12.06

  42. Yoshimi A, Aleksic B, Kunimoto S, Kushima I, Nakamura Y, Kimura H, Takasaki Y, Wang C, Xing J, Hirakawa A, Ikeda M, Iwata N, Ozaki N.. Transcriptome analysis of lymphoblastoid cell line from schizophrenia and bipolar disorder. . XXII World Congress of Psychiatric Genetics 2014.10.16

  43. Kato T, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Hirakawa A, Iwano S, Yokoi K. . The contact length between the tumor contour and lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. . 28th Annual Meeting of the European Association for Cardio-Thoracic Surgery 2014.10.11

  44. Asano J, Hirakawa A, Hamada C.. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model. . 35th International Society for Clinical Biostatistics 2014.08.24

  45. Nara E, Yunokawa M, Yonemori K, Doutani C, Shimizu K, Mimaki Y, Oomatsu N, Komatsu M, Hirakawa A, Shimizu C, Fujiwara Y, Tamura K.. Identifying the social support needs of young cancer patients in Japan. . European Society of Medical Oncology 2014.06.25

  46. Okuma H, Koizumi F, Hirakawa A, Nakatochi M, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis.. European Society of Medical Oncology 2014.06.25

  47. Tanaka R, Yonemori K, Hirakawa A, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. . Risk factors for developing skeletal-related events associated with metastatic breast cancer patients receiving bone-modifying agents.. European Society of Medical Oncology 2014.06.25

  48. Yoshimi A, Kunimoto S, Yamada S, Aleksic B, Hirakawa A, Nagai T, Ozaki N. . Proteomic analysis of the lymphoblastoid cell line derived from Japanese schizophrenic patients. . 29th CINP World Congress of Neuropsychopharmacology 2014.06.22

  49. Usami N, Yokoi K, Murotani K, Hirakawa A, Tabata C, Soejima T, Kamikonya N, Tanaka F, Yamanaka T, Okada M, Hasegawa S, Nakano T. . Assessment of postoperative complications after the first all Japan multi-institutional trial of induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.. 15th World Conference on Lung Cancer 2013.10.27

  50. Nara E, Kodaira M, Hirakawa A, Noguchi E, Yamamoto H, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Risk factors of eribulin mesylate. 第11回日本臨床腫瘍学会学術集会 2013.08.29

  51. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . 34th International Society for Clinical Biostatistics 2013.08.25

  52. Kakurai Y, Sano M, Hirakawa A, Hamada C.. A dose-finding approach based on cohort partitioning for combination of two agents in Phase I trials in oncology.. 34th International Society for Clinical Biostatistics 2013.08.25

  53. Nomura S, Hirakawa A, Hamada C.. Sample size calculation for confirming both PFS and OS simultaneously in cancer clinical trials.. 34th International Society for Clinical Biostatistics 2013.08.25

  54. Hirakawa A, Hamada C. . A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. . XXVIth International Biometrics Conference 2012.08.26

  55. Yamada K, Hirakawa A, Hamada C. . Operating characteristics of the penalized Cox regression analysis in high-dimensional microarray data.. XXVIth International Biometrics Conference 2012.08.26

  56. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . XXVIth International Biometrics Conference 2012.08.26

  57. Mano H, Hirakawa A, Hamada C.. Improvement of Trim and Fill method to adjust publication bias in meta-analysis using the clinical trial registration system. . XXVIth International Biometrics Conference 2012.08.26

  58. Atsumi J, Hirakawa A, Hamada C.. A new allocation method for balancing prognostic continuous and categorical variables in clinical trials.. XXVIth International Biometrics Conference 2012.08.26

  59. Asakawa T, Hirakawa A, Hamada C.. A dose-finding method using bayesian model averaging for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.. XXVIth International Biometrics Conference 2012.08.26

  60. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . XXVIth International Biometrics Conference 2012.08.26

  61. Hirakawa A, Hamada C. . An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. . XXVIth International Biometrics Conference 2012.08.26

  62. Hirakawa A, Hamada C.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.. 3rd East Asia Regional Biometric Conference 2012.02.02

  63. Asano J, Hirakawa A, Hamada C.. A stepwise variable selection for a cure model.. 3rd East Asia Regional Biometric Conference 2012.02.02

  64. Kaneko S, Yamada K, Hirakawa A, Hamada C.. Estimating the false positive rate in a high-dimensional regression model in cancer prognostic studies with microarrays. . 3rd East Asia Regional Biometric Conference 2012.02.02

  65. Hirakawa A, Kaneko S, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . Pacific Symposium on Biocomputing 2012.01.03

  66. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. 日本バイオインフォマティクス学会 2011.11.08

  67. Hirakawa A, Hamada C.. Sample size calculation for a regularized t-statistic in microarray experiments. 日本バイオインフォマティクス学会 2011.11.08

  68. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yamamoto H, Fujiwara Y.. Content analysis of “the guidance for proper usage” that are distributed to medical oncologists for promoting oncology pharmaceutical safety. . European Multidisciplinary Cancer Congress 2011.09.23

  69. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita T, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y.. Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

  70. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Kodaira M, Tomomatsu J, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Tsuda H, Fujiwara Y. . Molecular profiling (MP) as a possible prognostic marker for patients with cancer of unknown primary (CUP) treated using platinum doublet (PD) chemotherapy.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

  71. Harano K, Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Makimoto A, Fujiwara.. Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, d-actinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

  72. Hashimoto K, Sasajima M, Ando M, Yonemori K, Hirakawa A, Tsuda H, Fujiwara Y.. Molecular profiling as a possible prognostic marker for patients with cancer of unknown primary treated using platinum doublet chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

  73. Asano J, Hirakawa A.. Covariate selection method in mixture cure model for survival data. . Eastern North American Region/International Biometric Society 2011.03.20

  74. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y. . Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity. . 22nd International Congress on Anti Cancer Treatment 2011.02.01

  75. Yamamoto H, Yonemori K, Hirakawa A, Shimizu C, Ando M, Katsumata N, Tamura K, Kinoshita T, Tsuda H, Fujiwara Y.. Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy. . European Society for Medical Oncology Congress 2010.10.08

  76. Hirakawa A, Hamada C, Yoshimura I.. A practical comparison of response-adaptive randomizations in clinical trials with binary responses.. 31th International Society of Clinical Biostatistics 2010.08.29

  77. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. . 31th International Society of Clinical Biostatistics 2010.08.29

  78. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. . Efficacy of taxane regimens in patients with metastatic angiosarcoma. . 21st International Congress on Anti-cancer Treatment 2010.02.01

  79. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S.. Participation of elderly patients in registered clinical trials for cancer drug applications in Japan. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  80. Kotani N, Katsumata N, Yonemori K, Hirakawa A, Yamamoto H, Ono M, Hirata T, Yunokawa M, Kouno T, Shimizu C, Tamura K, Fujiwara Y. . Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  81. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Fujiwara Y. . Identification of clinical decision making factors in the treatment of geriatric patients with metastatic or recurrent breast cancer.. The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  82. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Shimizu C, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y.. Prediction of progressive disease using tumor marker in breast cancer patients without target lesion in first-line chemotherapy.. ASCO Breast Cancer Symposium 2009.10.08

  83. Hirata T, Yonemori K, Hirakawa A, Kouno T, Shimizu C, Tamura K, Ando M, Katsumata N, Fujiwara Y.. A retrospective comparison of pleural progression free survival between systemic therapy alone and pleurodesis followed by preceding systemic therapy in breast cancer patients with malignant pleural effusion. . ASCO Breast Cancer Symposium 2009.10.08

  84. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation for a regularized t-statistic in microarray experiments.. 30th International Society of Clinical Biostatistics 2009.08.23

  85. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. An adjusted test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray experiments. . XX IVth International Biometric Conference 2008.07.13

  86. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. A test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray data analysis.. 1st East Asia Regional Biometrics Conference 2007.12.09

  87. Hirakawa A, Sato Y, Hamada C, Yoshimura I. . A statistical method to estimate sensitivity and specificity for identifying marker genes with microarray data. . 28th International Society of Clinical Biostatistics 2007.07.29

  88. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I.. Estimating the false discovery rate using a normal mixture distribution with microarray data.. XX III International Biometric Conference 2006.06.16

  89. Sato Y, Ando H, Hirakawa A, Suganami H, Hamada C, Yoshimura I, Yoshida T, Yoshimura K. . Multiple imputation method for SNP typing data in linkage disequilibrium mapping of polygenic traits. . Joint Statistical Meetings 2005.08.07

  90. 上村夕香理,荒木康弘,安藤友紀,石黒智恵子,坂巻顕太郎,平川晃弘,柴田大朗.. 生物統計学的な観点からのワクチン開発における治験計画の立案の迅速化のための研究. . 第12回レギュラトリーサイエンス学会学術集会 2022.09.09 東京都千代田区

  91. 北林 遼,野村 尚吾,佐藤 宏征,平川 晃弘. バスケット試験における治療効果の類似度を考慮したベイズ流試験デザイン. 2022統計関連学会連合大会 2022.09.05 東京都武蔵野市(ハイブリッド開催)

  92. 青山薫英,内山千代子,林滉一朗,徳田糸代,平川晃弘,山本幸夫,田村好拡,小林恒,村下公一,中路重之. 日本の地域在住一般住民におけるデンタルフロスの使用習慣と歯周ポケット深さ・現在歯数との縦断的関連性. 第65回秋季日本歯周病学会学術大会 2022.09.02 宮城県仙台市

  93. 太田 絵里, 須藤 毅顕, 中林 潤, Heewon Park, 平川 晃弘, 木下 淳博, 角 勇樹. 臨床検査技師AI教育のためのクラウドコンピューター環境構築. 第16回日本臨床検査学教育学会学術大会 2022.08.19 埼玉県日高市

  94. 高橋健太,温泉川真由,佐藤宏征,平川晃弘,小林康祐,金尾祐之,宮坂尚幸,野村弘行,青木大輔,横山良仁,竹原和宏. JGOG2043におけるI-II期子宮体癌を対象とした新しい再発予測モデルの再現性及び予測精度の検証. 第64回日本婦人科腫瘍学会学術講演会 2022.07.14 福岡県久留米市

  95. 齊藤利雄,竹島泰弘,水野勝広,橋口昭大,佐橋健太郎,平川晃弘,川田洋充,勝野雅央. PRIME-SMA:脊髄性筋萎縮症患者を対象とした手の作業能力に対するリスジプラムの有効性評価方法に関する研究プロトコル. 第64回日本小児神経学会学術集会 2022.06.25 群馬県高崎市

  96. 橋口昭大,竹島泰弘,水野勝広,齊藤利雄,佐橋健太郎,平川晃弘,川田洋充,勝野雅央. SMA患者の⼿の作業能⼒に対するリスジプラムの有効性評価⽅法:研究プロトコル. 第63回日本神経学会学術大会 2022.05.20 東京都千代田区

  97. 佐立崚,平川晃弘,藤原武男. がん第 I 相試験における用量増減のリスクを考慮した model-assisted デザインの提案. 日本計量生物学会年会 2022.05.13 東京都葛飾区(ハイブリッド開催)

  98. 齊藤 利雄, 竹島 泰弘, 水野 勝広, 橋口 昭大, 佐橋 健太郎, 平川 晃弘, 川田 洋充, 勝野 雅央. PRIME-SMA 脊髄性筋萎縮症患者を対象とした手の作業能力に対するリスジプラムの有効性評価方法に関する研究プロトコル. 脳と発達 2022.05.01

  99. 中野梨香子, 青山礼奈, 曾根田ますみ, 小峯万里, 石山千明, 山下直美, 野口綾子, 平川晃弘, 佐藤宏征.. 病院集中治療部における身体拘束減少へ向けた適正化への取り組み−看護師を対象とした前向き調査より−. 第49回日本集中治療医学会学術集会 2022.03.18

  100. Sudo K. Shimizu T. Yonemori K. Koyama T. Matsui N. Kamikura M. Tomatsuri S. Sumiyoshi Okuma H. Shimoi T. Noguchi E. Kojima Y. Hirakawa A. Sadachi R. Okita N. Nakamura K. Yamamoto N. Fujiwara Y.. A phase Ⅱ study evaluating the clinical efficacy of MDM2 inhibitor, milademetan, in patients with intimal sarcoma (NCCH1806/MK004). 第19回日本臨床腫瘍学会学術集会 2022.02.17

  101. Matsumoto K. Nishikawa T. Hirakawa A. Kawasaki M. Tomatsuri S. Nagasaka Y. Nakamura K. Hasegawa K. Mori M. Hirashima Y. Takehara K. Ariyoshi K. Kato T. Yagishita S. Hamada A. Yoshida H. Yonemori K.. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma: STATICE TRIAL (NCCH1615). 第19回日本臨床腫瘍学会学術集会 2022.02.17

  102. 平川晃弘. マスタープロトコル試験. 日本臨床試験学会第13回学術集会総会 2022.02.04

  103. 石渡 泰芳, 永田 将司, 小林 朋史, 今井 耕輔, 高木 正稔, 金兼 弘和, 森尾 友宏, 平川 晃弘, 高橋 弘充. 原発性免疫不全症候群の小児患者における母集団薬物動態解析モデルを用いたブスルファン投与設計法の開発. 日本臨床薬理学会学術総会抄録集 2021.12.01

  104. 新妻邦泰,大沢伸一郎,遠藤英徳,出江紳一,安宅航太,平川晃弘,岩野政雄,冨永悌二. 脳梗塞患者を対象とした他家Muse細胞製品CL2020の治療成績:ランダム化プラセボ対照二重盲検試験. 日本脳神経外科学会第80回学術総会 2021.10.27

  105. 平川晃弘. マスタープロトコルを用いた臨床試験:医薬品開発の効率化と加速化を目指して. DIA Master Protocol Workshop 2021 2021.05.18

  106. 新垣誉子,小島勇貴,西川忠曉,大熊ひとみ,一村昌彦,沖田南都子,中村健一,平川晃弘,山本昇,米盛勧. 切除不能胞巣状軟部肉腫に対するAtezolizumabの医師主導治験. JSMO 2021 2021.02.18

  107. 平川晃弘. 希少疾患領域の治験におけるベイズ流アプローチの利用可能性. AMED医薬品等規制調和・評価研究事業合同シンポジウム 2020.12.08

  108. 平川晃弘. 希少がん・希少フラクション領域の臨床試験デザイン・統計解析の最前線. 第3回日本サルコーマ治療研究学会学術集会 2020.02.21

  109. 平川晃弘. 医薬品開発・臨床研究における疾患レジストリの活用の実際. 第33回日本計算機統計学会 2019.12.01

  110. 平川晃弘. アダプティブデザインの理論と実践. 日本計量生物セミナー 2019.11.14

  111. 平川晃弘. ランダム化対照試験. 第60回日本小児血液・がん学会学術集会 2018.11.15

  112. 平川晃弘. Precision Medicine を目指した適応的デザインーバスケットデザインの理論と実践ー. 2018年度計量生物学会年会チュートリアル 2018.03.30

  113. 平川晃弘. 臨床研究における研究計画書作成の統計学的ポイント. 第33回日本環境感染学会総会・学術集会 2018.02.24

  114. 平川晃弘. 希少がん・希少フラクション領域の臨床試験デザイン・統計解析の最前線. 第3回日本サルコーマ治療研究学会学術集会 2018.02.21

  115. 平川晃弘. 臨床試験におけるデータモニタリング委員会の役割と責務. ARO協議会第5回生物統計セミナー 2018.02.03

  116. 平川晃弘. 希少がん・希少フラクション領域の臨床開発オプションを考える. 第14回DIA日本年会 2017.11.14

  117. 平川晃弘. 変化するがん第1相試験の役割. 第14回DIA日本年会 2017.11.14

  118. 平川晃弘. 疾患レジストリデータを取り巻く規制案と現状. 第14回DIA日本年会 2017.11.13

  119. 平川晃弘. アカデミア臨床試験におけるデータモニタリング委員会の役割と責務. ARO協議会第5回学術集会 2017.09.25

  120. 平川晃弘. 新規抗がん剤と用量探索デザインの趨勢. 2017年度 統計関連学会連合大会 2017.09.05

  121. 志村将司,平川晃弘,五所正彦. 中間解析を伴う臨床試験における条件付きバイアス調整推定量の性能評価. 2017年統計関連学会連合大会 2017.09.04

  122. 平川晃弘. 医療統計を学会発表や論文作成に役立てる. 第26回日本心血管インターベンション治療学会(CVIT2017) 2017.07.05

  123. 加藤凌輔,平川晃弘,浜田知久馬. 抗がん剤第Ⅰ相試験における経時データを使用した用量探索の方法に関する研究. 日本計量生物学会年会 2017.03.16

  124. 島村文也,平川晃弘,浜田知久馬. 抗がん剤併用療法の第I/II 相試験における2 段階デザインを用いた用量探索. 日本計量生物学会年会 2017.03.16

  125. 佐藤宏征,平川晃弘,浜田知久馬. がん分子標的薬の用量探索法. 日本計量生物学会年会 2017.03.16

  126. 平川晃弘. 個別化医療を目指した先進的試験デザイン. 第13回DIA日本年会 2016.11.15

  127. 平川晃弘. 疾患レジストリを用いた医薬品開発の効率化. 第13回DIA日本年会 2016.11.14

  128. 平川晃弘. がん第1 相試験における用量探索法の変遷. 2016年度統計関連学会連合大会 2016.09.06

  129. 平川晃弘. コメディカルのためのわかりやすい医療統計学. 第25回日本心血管インターベンション治療学会(CVIT2016) 2016.07.06

  130. 平川晃弘. レジストリーデータは医薬品開発に活用できるか?. 日本臨床試験学会第7回学術集会総会 2016.03.11

  131. 平川晃弘,木下文恵,森由美子,清水忍. 抗悪性腫瘍薬の臨床データパッケージ分析からみる今後の課題. 日本臨床試験学会第7回学術集会総会 2016.03.11

  132. 倉田美穂,柳澤昌実,平川晃弘,神田善伸,諫田淳也,栗田尚樹,鍬塚八千代,松尾恵太郎,一戸辰夫,熱田由子. 一元管理登録(TRUMP) データを用いたCase Matched Control(1:k)抽出方法の検討. 日本臨床試験学会第7回学術集会総会 2016.03.11

  133. 21. 清水 忍,豊永亜希子,細野恵美,城田真里,鈴木 哲,末竹幸広,平井寿子,西村千穂,田邊めぐみ,小倉佳奈,川影美千代,安藤幸子,鍬塚八千代,平川晃弘,加藤勝義,安藤昌彦,水野正明,片桐 渉,日比英晴. 再生医療安全性確保法に基づく先進医療Bの臨床試験実施体制の構築について~骨髄由来間葉系細胞を用いた顎骨欠損に対する骨再生医療研究~. 日本臨床試験学会第7回学術集会総会 2016.03.11

  134. 中野春美,中島智美,永野優子,山口真佐美,土方靖浩,鈴木啓介,橋詰淳,山田晋一郎,稲垣智則,平川晃弘,木下文恵,勝野雅央,祖父江元. 医師主導臨床試験における逸脱症例への多職種の対応と考察. 日本臨床試験学会第7回学術集会総会 2016.03.11

  135. 平川晃弘,木下文恵,森由美子,水野正明. 名古屋大学における医師主導臨床研究の統計解析支援業務に関する現状. 日本臨床試験学会第7回学術集会総会 2016.03.11

  136. 平川晃弘. 頻度流標本サイズ設定. ARO協議会第3回生物統計セミナー 2016.01.30

  137. 平川晃弘. 医薬品開発におけるバイオマーカーの活用. PhUSE 2015 2015.12.03

  138. 平川晃弘. 臨床試験で必要となる統計学~その考え方とは~. 第33回日本神経治療学会総会 2015.11.26

  139. 平川晃弘. アカデミア研究における遺伝子探索. 第12回DIA日本年会 2015.11.15

  140. 平川晃弘. 頻度流標本サイズ設定. ARO協議会第3回学術集会 2015.09.18

  141. 平川晃弘. コメディカルが知っておくべき医療統計学. 第23回日本心血管インターベンション治療学会(CVIT2015) 2015.08.01

  142. 金子周平,平川晃弘,浜田知久馬. 遺伝子発現量データに基づくLasso を用いた生存時間予測モデルの構築に関する研究. 日本計量生物学会年会 2015.03.12

  143. 平川晃弘,清水忍,鍬塚八千代,室谷健太,木下文恵,中杤昌弘,杉下明隆,飯島祥彦,加藤勝義,安藤昌彦,水野正明. 名古屋大学における臨床研究認定者制度に関する取組み. 日本臨床試験学会第6回学術集会総会 2015.02.20

  144. 平川晃弘,木下文恵,鍬塚八千代,室谷健太,森由美子,中村真由美,杉下明隆,清水忍,水野正明. 中部先端医療開発円環コンソーシアムにおけるWeb登録・割付システムの紹介. 日本臨床試験学会第6回学術集会総会 2015.02.20

  145. 宮内理世,久保田誠司,伊藤善之,伊藤淳二,中原理絵,川村麻里子,岡田徹,長縄 慎二,吉川史隆,平川晃弘. 名大病院における子宮頸癌術後の(化学)放射線療法による治療成績の検討. 日本放射線腫瘍学会第27回学術大会 2014.12.11

  146. 平川晃弘. 広い視点を持った開発担当者・審査員を育てるために ~境界を超えた人材育成と人材交流の必要性~医療機関の立場から. 第11回DIA日本年会 2014.11.16

  147. 島田和之,島田聡子,杉本慶樹,早川文彦,片山幸,平川晃弘,中村栄男,瀬戸加大,直江知樹,冨田章裕,清井仁. 異種移植モデルを用いた血管内大細胞型B細胞リンパ腫の病態解析. 第76回日本血液学会学術集会 2014.10.31

  148. 清水忍,平川晃弘,鍬塚八千代,室谷健太,木下文恵,中杤昌弘,杉下明隆,飯島祥彦,加藤勝義,安藤昌彦,水野正明. 名古屋大学における臨床研究認定者制度に関する取組み. ARO協議会第2回学術集会 2014.09.23

  149. 浅野淳一,平川晃弘,浜田知久馬. Cox proportional hazards cure modelにより推定した治癒確率の予測精度の評価法. 2014年度統計関連学会連合大会 2014.09.13

  150. 平川晃弘. 良い論文を書くための統計学. 東海ライブ研究会,第4回豊橋ライブデモンストレーションコース 2014.05.30

  151. 平川晃弘. FDA, EMAのM&Sの公表事例と各規制当局の動向. 第3回レギュラトリーサイエンス学会学術大会 2013.11.03

  152. 大篭友博, 平野健一, 小林和克, 松本智宏, 名取貴光, 平川晃弘, 今釜史郎, 門松健治. ケラタン硫酸の欠損はALSの早期病態形成を加速させる. Neuro 2013 2013.06.20

  153. 加倉井靖之,平川晃弘,浜田知久馬. 抗がん剤併用療法第I相試験におけるコホート分割法に基づくベイズ流用量探索. 2013年度日本計量生物学会 2013.05.23

  154. 原野謙一,平川晃弘,酒井瞳,加藤隆之,鈴木啓介,渡辺幸子,勝俣範之. DPCデータを用いた卵巣がん初回化学療法における G-CSF使用施設間格差の分析. 第50回日本癌治療学会学術集会 2012.10.25

  155. 谷山智子,橋本堅治,平川晃弘,勝俣範之,公平誠,米盛勧,温泉川真由,清水千佳子,田村研治,安藤正志,藤原康弘. 標準化学療法抵抗となった患者の予後予測. 第10回日本臨床腫瘍学会学術集会 2012.07.26

  156. 田辺裕子,清水千佳子,平川晃弘,友松純一,公平誠,温泉川真由,米盛勧,田村研治,安藤正志,藤原康弘. 化学療法による抹消神経障害の評価における知覚・痛覚定量分析装置(ペインビジョン)の有用性の検討. 第20回乳癌学会学術総会 2012.06.28

  157. 渥美淳,平川晃弘,浜田知久馬. 臨床試験で量的・質的な予後因子をバランスさせる割付方法. 2012年度日本計量生物学会年会 2012.05.25

  158. 金子周平,平川晃弘,浜田知久馬. マイクロアレイデータを用いたCox回帰に基づく遺伝子選択. 2012年度日本計量生物学会年会 2012.05.25

  159. 斉藤真理,龍島靖明,米盛勧,平川晃弘,西垣玲奈,牧野好倫,横手信昭,安藤正志,藤原康弘,山本弘史. 製薬企業発行の抗がん剤患者説明用パンフレットの現状調査. 第49回 日本癌治療学会学術集会 2011.10.27

  160. 平川晃弘,佐藤泰憲,寒水孝司,浜田知久馬,吉村功. マイクロアレイデータにおける疾患感受性遺伝子の同定法に関する統計学的検討. 第65回日本癌学会学術総会 2006.09.28

  161. 平川晃弘,佐藤泰憲,寒水孝司,浜田知久馬,吉村功. マイクロアレイデータにおけるFDRに基づくカットオフ値の選定方法に関する検討. 統計関連学会連合大会 2006.09.05

  162. 平川晃弘,佐藤泰憲,寒水孝司,浜田知久馬,吉村功. マイクロアレイデータにおける混合正規分布を用いたFDRの推定法. 計量生物学会シンポジウム 2006.05.25

▼全件表示

受賞学術賞 【 表示 / 非表示

  • 奨励賞,日本計量生物学会,2016年

その他業績 【 表示 / 非表示

  • 「低酸素環境における核内の遺伝子配置の大規模解析」 ー低酸素に応じて動く遺伝子の同定ー,2022年05月

  • AMED医薬品等規制調和・評価研究事業合同シンポジウム 「これからの臨床試験:新機軸の展開」,2020年12月

    医薬品等の有効性及び安全性を評価する新しい枠組み(ベイズ流アプローチ、疾患レジストリデータの利活用)に関する討論

 

担当授業科目(学内) 【 表示 / 非表示

  • 臨床統計III

  • 先制医療学実習

  • がんの社会医学

担当授業科目(学外) 【 表示 / 非表示

  • 応用線形代数学,東京理科大学大学院

  • 臨床研究コース,明治薬科大学

  • 臨床試験,名古屋大学

  • 臨床試験方法論,東京大学大学院

  • 臨床試験方法論,東京理科大学大学院

  • 臨床試験方法論,久留米大学大学院

▼全件表示